ABL1 is an inclusion eligibility criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 4 are closed. Of the trials that contain ABL1 status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (1 open) and 1 is no phase specified (0 open) [3].

AFF1 is an inclusion eligibility criterion in 4 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain AFF1 status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) and 1 is no phase specified (0 open) [3].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCL2 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BCR is an inclusion eligibility criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 4 are closed. Of the trials that contain BCR status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (1 open) and 1 is no phase specified (0 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

CCND1 is an inclusion eligibility criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain DEK status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [3].

ELL is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain ELL status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [3].

FLT3 is altered in 2.78% of lymphoplasmacytic lymphoma patients [2].

FLT3 is an inclusion eligibility criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 4 are closed. Of the trials that contain FLT3 status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (1 open) and 1 is no phase specified (0 open) [3].

IGH is an inclusion eligibility criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

IKZF1 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) [3].

IRAK1 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IRAK1 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

JAK2 is altered in 2.78% of lymphoplasmacytic lymphoma patients [2].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

JAK3 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is an inclusion eligibility criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [3].

KMT2A is an inclusion eligibility criterion in 4 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain KMT2A status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) and 1 is no phase specified (0 open) [3].

MECOM is an inclusion eligibility criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain MECOM status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (2 open) and 1 is no phase specified (0 open) [3].

MLF1 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLF1 status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

MLLT1 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain MLLT1 status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain MLLT10 status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain MLLT3 status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain MLLT4 status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MYC is an inclusion eligibility criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

MYD88 is altered in 41.67% of lymphoplasmacytic lymphoma patients [2].

MYD88 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

NPM1 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NPM1 status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

NRIP3 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain NRIP3 status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [3].

NUP214 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain NUP214 status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [3].

PBX1 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain PBX1 status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain RPN1 status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (2 open) and 1 is no phase specified (0 open) [3].

RUNX1 is altered in 2.78% of lymphoplasmacytic lymphoma patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

TCF3 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain TCF3 status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) [3].

TP53 is altered in 11.11% of lymphoplasmacytic lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain TP53 status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [3].

TYK2 is an inclusion eligibility criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TYK2 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].